AC-262536: Emerging SARM Compound, Partial Androgen Receptor Agonist Research & Selectivity Profile

A New Entry in the SARM Research Landscape

AC-262536 is a non-steroidal selective androgen receptor modulator (SARM) that has attracted growing attention in research circles for its partial agonist profile at the androgen receptor. First described in a 2007 patent by Acadia Pharmaceuticals (hence the “AC” prefix), this compound occupies a distinct pharmacological niche — it activates the androgen receptor with lower maximal efficacy than testosterone or DHT, producing tissue-selective anabolic effects while maintaining a favorable androgenic-to-anabolic ratio in preclinical models.

Among the growing family of SARMs under investigation, AC-262536 stands out for the simplicity of its pharmacological profile. Where some SARMs are full agonists with tissue selectivity arising from differential coactivator recruitment, AC-262536 achieves selectivity partly through its partial agonist nature — it cannot drive maximal receptor activation regardless of concentration, placing a ceiling on both desired and undesired effects.

Androgen Receptor Binding Kinetics

AC-262536 binds to the ligand-binding domain (LBD) of the androgen receptor with moderate affinity. In competitive binding assays, it displaces radiolabeled DHT from AR with a Ki in the nanomolar range, though its absolute affinity is lower than that of steroidal androgens or full-agonist SARMs like LGD-4033 or RAD-140.

The partial agonism is evident in transcriptional reporter assays. In cells transfected with androgen-responsive luciferase reporters, AC-262536 produces approximately 65-70% of the maximal transcriptional activation achieved by DHT at saturating concentrations. This submaximal ceiling is intrinsic to the compound’s interaction with the receptor — increasing AC-262536 concentration beyond the point of receptor saturation does not increase transcriptional output beyond this plateau.

Partial agonism has a second pharmacological consequence: in the presence of full agonists, AC-262536 can function as a partial antagonist. By occupying androgen receptors and activating them submaximally, it competes with endogenous androgens for binding and reduces the net androgenic signal when testosterone or DHT concentrations are high. This dual agonist/antagonist behavior depending on the hormonal environment adds nuance to its pharmacological profile.

Anabolic-to-Androgenic Ratio

The defining metric for SARM selectivity is the ratio of anabolic effects (typically measured as levator ani muscle mass in rodent models) to androgenic effects (prostate or seminal vesicle weight). In castrated rat bioassays, AC-262536 demonstrated approximately 66% of the anabolic efficacy of testosterone (muscle accretion) while showing only 27% of testosterone’s androgenic effect (prostate stimulation).

This yields an anabolic-to-androgenic ratio of approximately 2.45:1 — meaning the compound’s muscle effects are roughly 2.5 times greater than its prostate effects relative to testosterone. For context, testosterone itself has a ratio of 1:1 by definition. Other SARMs show varying ratios: LGD-4033 achieves higher absolute anabolic efficacy but with a different selectivity profile; RAD-140 demonstrates a notably high ratio in some assay systems.

The practical implication of AC-262536’s moderate anabolic efficacy ceiling is that it may produce measurable but bounded muscle effects in research models — substantial enough for detection but limited by the partial agonism that prevents full receptor activation. This ceiling could be viewed as either a limitation or a feature, depending on the research context.

Tissue Selectivity Mechanisms

How does AC-262536 produce different effects in muscle versus prostate? Three mechanisms are proposed, none mutually exclusive.

First, differential coactivator/corepressor recruitment. The androgen receptor, once ligand-bound, interacts with tissue-specific transcriptional coregulators that determine which genes are activated. Different ligands stabilize different AR conformations, which in turn recruit different coregulator complements. AC-262536’s binding pose in the LBD may favor coactivators abundant in skeletal muscle while poorly recruiting those enriched in prostate tissue.

Second, differential metabolism. Prostate tissue expresses 5α-reductase, which converts testosterone to the more potent DHT. Non-steroidal SARMs like AC-262536 are not substrates for 5α-reductase, so they cannot be locally amplified in prostate tissue the way steroidal androgens are. This enzymatic bypass contributes to reduced androgenic impact in 5α-reductase-expressing tissues.

Third, partial agonism itself may interact with receptor density. Tissues with high AR expression (prostate) may be more sensitive to the difference between a full and partial agonist than tissues with moderate AR expression (muscle), where the partial agonist may achieve near-maximal functional response through receptor reserve effects.

Comparison with Other SARMs

Within the SARM research family, AC-262536 occupies a position of moderate potency with relatively clean selectivity. Compared to LGD-4033 (full agonist, high potency, strong anabolic effects but with measurable hormonal suppression), AC-262536 is less potent but potentially less suppressive due to its partial agonist ceiling. Compared to RAD-140 (which shows high anabolic-to-androgenic selectivity with full agonist efficacy in some systems), AC-262536 offers a simpler pharmacological mechanism — its selectivity does not depend primarily on tissue-specific metabolism but on intrinsic receptor pharmacology.

These comparisons are drawn from preclinical data only. No human studies have been published for AC-262536, and its clinical development status remains preclinical. Researchers evaluating this compound should note that rodent-to-human translation for SARMs has proven inconsistent — some compounds perform better in humans than preclinical data predicted, others worse.

Hormonal Axis Considerations in Research Models

All androgen receptor agonists — including partial agonists — have the potential to suppress endogenous testosterone production through hypothalamic-pituitary-gonadal (HPG) axis feedback. In preclinical models, AC-262536 produced measurable but modest LH suppression at anabolic concentrations, consistent with its partial agonist nature. Full agonists like testosterone produce near-complete LH suppression at equivalent receptor occupancy, while AC-262536’s submaximal receptor activation produces proportionally less hypothalamic feedback inhibition.

This characteristic is relevant for researchers designing chronic administration protocols in rodent models, where the degree of HPG axis suppression influences circulating testosterone concentrations and complicates interpretation of AR-mediated endpoints.

Research Status and Availability

AC-262536 remains a research compound with no regulatory approvals for any application. Published data is limited primarily to preclinical pharmacology, and its structure-activity relationships have been explored mainly in the context of Acadia Pharmaceuticals’ SARM discovery program. For research laboratories evaluating SARM selectivity mechanisms, AC-262536 offers a useful pharmacological tool: its partial agonism provides a defined ceiling for comparison with full agonist SARMs, and its clean selectivity profile simplifies interpretation of tissue-specific outcomes.

Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.